Novo Nordisk's new obesity drug data disappoints again, shares fall

Bangkok Post Group 2025-03-11

Views 577

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market. - REUTERS

Share This Video


Download

  
Report form